徐盛涛 - 中国药科大学

个人简介

教育经历 2010/09-2015/06，中国药科大学，药学院，药物化学，博士 2006/09-2010/06，中国药科大学，药学院，制药工程，学士工作经历 2018/07-至今，中国药科大学，药学院，副研究员 2015/07-2018/06，中国药科大学，药学院，博士后

研究领域

(1) 基于天然产物的新药研发 (2) 蛋白降解药物开发 (3) 药物合成新技术研究

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Wu, H.Y.; Yao, H.*; He, C.; Jia, Y.L.; Zhu, Z.Y.; Xu, S.T.*, Li, D.H.; Xu, J.Y.* Molecular glues modulate protein functions by inducing protein aggregation: A promising therapeutic strategy of small molecules for disease treatment. Acta Pharm. Sin. B 2022; doi.org/10.1016/j.apsb.2022.03.019. (IF: 14.903) Xie, S.W.; Sun, Y.; Liu, Y.L.; Li, X.N.; Li, X.N.; Zhong, W.Y.; Zhan, F.Y.; Zhu, J.J.; Yao, H.; Yang, D.H.; Chen, Z.S.; Xu, J.Y.*; Xu, S.T.* Development of Alectinib-Based PROTACs as Novel Potent Degraders of Anaplastic Lymphoma Kinase (ALK). J. Med. Chem. 2021;64:9120-40. (IF: 8.039) Xu, S.T.; Yao, H.; Qiu, Y.Y.; Zhou, M.Z.; Li, D.H.*; Wu, L.*; Yang, D.H.; Chen, Z.S.; Xu, J.Y.* Discovery of Novel Polycyclic Heterocyclic Derivatives from Evodiamine for the Potential Treatment of Triple-Negative Breast Cancer. J. Med. Chem. 2021;64:17346-56. (IF: 8.039) Yao, H.; Xie, S.W.; Ma, X.Q.; Liu, J.K.; Wu H.Y.; Lin A.J.; Yao, H.Q.; Li, D.H.; Xu, S.T.*; Yang, D.H.; Chen, Z.S.; Xu, J.Y.* Identification of a potent oridonin analogue for treatment of triple-negative breast cancer. J. Med. Chem. 2020;63: 8157-78. (IF: 7.446) Yao, H.; Luo, S.S.; Liu, J.K.; Xie, S.W.; Liu, Y.P.; Xu, J.Y.;* Zhu, Z.Y.; Xu, S.T.* Controllable thioester-based hydrogen sulfide slow-releasing donors as cardioprotective agents. Chem. Commun. 2019;55: 6193-96. (IF: 6.222) Yao, H.; Xu, F.J.; Wang, G.Y.; Xie, S.W.; Li, W.L.; Yao, H.Q.; Ma, C.; Zhu, Z.Y.; Xu, J.Y.;* Xu, S.T.*. Design, synthesis, and biological evaluation of truncated deguelin derivatives as Hsp90 inhibitors. Eur. J. Med. Chem. 2019;167: 485-98. (IF: 6.514) Li, W.L.; Shuai, W.; Sun, H.H.; Xu, F.J.; Bi, Y.; Xu, J.Y.;* Ma, C.; Yao, H.Q.; Zhu, Z.Y.; Xu, S.T.;* Design, synthesis and biological evaluation of quinoline-indole derivatives as anti-tubulin agents targeting the colchicine binding site. Eur. J. Med. Chem. 2019;163: 428-42. (IF: 6.514) Li, W.L.; Xu, F.J.; Shuai, W.; Sun, H.H.; Yao, H.; Ma, C.; Xu, S.T.; * Yao, H.Q.; Zhu, Z.Y.; Yang, D.H.; Chen, Z.S.; Xu, J.Y.* Discovery of novel quinoline-chalcone derivatives as potent antitumor agents with microtubule polymerization inhibitory activity. J. Med. Chem. 2019;62: 993-1013. (IF: 6.205) Xu, S.T.; Yao, H.; Luo, S.S.; Zhang, Y.K.; Yang, D.H.; Li, D.H.; Wang, G.Y.; Hu, Mei.; Qiu, Y.Y.; Wu, X.M.; Yao, H.Q.;* Xie, W.J.; Chen, Z.S.;* Xu, J.Y.* A novel potent anticancer compound optimized from a natural oridonin scaffold induces apoptosis and cell cycle arrest through the mitochondrial pathway. J. Med. Chem. 2017;60: 1449-68. (IF: 6.253) Xu, S.T.; Luo, S.S.; Yao, H.; Cai, H.; Miao, X.M.; Wu, F.;* Yang, D.H.; Wu, X.M.; Xie, W.J.; Yao, H.Q.; Chen, Z.S.; Xu, J.Y.* Probing the anticancer action of oridonin with fluorescent analogues: Visualizing subcellular localization to mitochondria. J. Med. Chem. 2016;59: 5022-34. (IF: 6.259)